NRX Pharmaceuticals, Inc. - Common Stock (NRXP)

NRx Pharmaceuticals (NASDAQ:NRXP) said it advanced several regulatory, manufacturing and clinical initiatives during the first quarter of 2026, including progress toward potential approval of its preservative-free ketamine product, KETAFREE, and preparations for an NDA filing for NRX-100. Founder,

HOPE Therapeutics, Inc., a subsidiary of NRx Pharmaceuticals, Inc. (NASDAQ: NRXP),

NRx said the FDA’s fast-track status makes NRX-100 eligible for the Commissioner’s National Priority Voucher program and the FDA’s Accelerated Approval pathway, and the company has already applied for a CNPV.

Favorable regulatory moves for a new drug application, blowout earnings and promising preclinical data triggered a flurry of discussions on Stocktwits for these tickers for the week ended April 11, 2025.

Chairman Jonathan Javitt said the resources committed are expected to bring NRx to the $100 million revenue threshold.

NRX Pharmaceuticals shares are moving higher on Tuesday after it invested $27 million in its subsidiary HOPE Therapeutics.

NRX shares are trading higher on Thursday after the company announced a joint acquisition initiative with Hope Therapeutics to buy Kadima Neuropsychiatry Institute.

Shares of MicroStrategy Incorporated (NASDAQ:MSTR) rose sharply in today's pre-market trading.

NRXP stock results show that NRX Pharmaceuticals missed analyst estimates for earnings per share the second quarter of 2024.

NRXP stock results show that NRX Pharmaceuticals missed analyst estimates for earnings per share the first quarter of 2024.